Drug Profile
Tinurilimab - Bayer/German Cancer Research Center
Alternative Names: BAY-1834942Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Bayer; German Cancer Research Center
- Developer Bayer
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CEACAM6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Canada (IV, Infusion)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Singapore (IV, Infusion)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)